Federal grant · project grant (b)
An R2 Non-neuroinvasive Herpes Simplex Virus Type 2 Vaccine - Project Summary There Is an Unmet Need for a Herpes Simplex Virus (HSV) Vaccine. We Propose to Develop a Live-attenuated HSV-2 Vaccine Based on Our R2 Technology Platform. R2 Vaccines Show Unprecedented Safety and Efficacy in Animal Models, and Offer Antigenicity Superior to Subunit/mrna and Single-round Vaccine Designs. R2 Vaccines Are Also the First Live-attenuated Alphaherpesvirus Vaccines That Lack Neuroinvasive Potential, and Thereby Are Incapable of Establishing Life-long Infections in the Nervous System. in Phase I of This Fast-track STTR Application, We Propose to: (i) Produce a HSV- 2 Self-excising Infectious Clone of a Low-passage Clinical Isolate, (II) Use the Clone to Produce a HSV-2 R2 Recombinant, and (III) Characterize the R2 Vaccine in Culture Side by Side With Our Existing HSV-1 R2 Vaccine Candidate. in Phase Ii, the HSV-2 R2 Vaccine Will Be Tested for Safety, Immunogenicity, and Efficacy in Mice and Guinea Pigs. This Work Will Provide the Foundation to Advance Product Development to Clinical Trials.
Committed
$1.7 Million
Paid out
$1.3M
76%
Committed, not yet paid
$406.8K
24%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…